Document Detail


IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy.
MedLine Citation:
PMID:  17490736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To assess the expression of IGF-1R in cervix carcinoma patients treated by radiotherapy and concomitant chemotherapy, its relation to clinical and pathologic prognostic factors and its role in predicting clinical outcome. MATERIALS AND METHODS: Sixty consecutive patients suffering from localized cervix carcinoma were prospectively included in this study from July 1999 to December 2003. Follow-up was closed in March 2006. Patients were staged following the TNM classification. All patients were referred to pelvic radiation up to doses of 45-64.80 Gy in 1.8-2 Gy fractions followed brachytherapy treatment. External radiotherapy boost was used in one patient not receiving brachytherapy (total dose up to 64.80 Gy). All patients received concomitant cisplatin at 40 mg/m(2)/week doses during pelvic radiation. IGF-1R expression was studied by immunohistochemistry in paraffin-embedded tumor tissue. RESULTS: IGF-1R was expressed in 56 patients (93.7%) and no relation was found with clinicopathological variables. Complete response after treatment was observed in 50 patients (83.3%). Clinical stage of the disease and clinical response to radiotherapy were the most important prognostic factors related to survival. Low (negative and fairly) IGF-1R tumor expression was correlated to better long-term Local and Regional Disease Free Survival (p=0.045), Disease-Free Survival (p=0.045), Cause-Specific Survival (p=0.032) and Overall Survival (p=0.021) in patients achieving a complete response. CONCLUSION: High IGF-1R expression is related with reduced long-term local control due to tumor disease radiochemoresistance in patients who initially respond to definitive radiotherapy and concomitant chemotherapy.
Authors:
Marta Lloret; Pedro Carlos Lara; Elisa Bordón; Beatriz Pinar; Agustin Rey; Orlando Falcón; Fernando Molano; Maria Antonia Hernández
Related Documents :
7867006 - Overexpression of cyclin d1 correlates with recurrence in a group of forty-seven operab...
14529656 - Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas...
18949396 - Expression of cytokeratin 7 predicts survival in stage i/iia/iib squamous cell carcinom...
19034576 - Immunohistochemically detected expression of p27(kip1) and skp2 predicts survival in pa...
15511466 - Arterial invasion predicts early mortality in stage i non-small cell lung cancer.
23701776 - What predicts the risk of recurrent lung metastases?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-05-08
Journal Detail:
Title:  Gynecologic oncology     Volume:  106     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-18     Completed Date:  2007-07-31     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8-11     Citation Subset:  IM    
Affiliation:
Radiation Oncology, Dr Negrin University Hospital, Las Palmas de Gran Canaria, Spain. mllosae@hotmail.com <mllosae@hotmail.com>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Combined Modality Therapy
Female
Humans
Middle Aged
Prospective Studies
Receptor, IGF Type 1 / biosynthesis*
Treatment Outcome
Uterine Cervical Neoplasms / drug therapy,  metabolism*,  radiotherapy,  therapy*
Chemical
Reg. No./Substance:
EC 2.7.10.1/Receptor, IGF Type 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells.
Next Document:  Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated wit...